Hims & Hers Stock Plummets on Weak Guidance

Hims & Hers shares hit 52-week low after Q1 2026 revenue guidance misses estimates by ~$50M, driven by regulatory headwinds in weight-loss drugs and a major acquisition.

Shares of Hims & Hers Health are facing intense selling pressure following the company's latest earnings report. While the telemedicine platform posted robust annual growth, its forward-looking guidance for the first quarter of 2026 fell far short of Wall Street's expectations. Investor confidence has been further shaken by regulatory challenges in the crucial weight-loss medication sector, even as management pursues a costly acquisition in Australia.

Regulatory Headwinds Drive Cautious Forecast

The primary factor behind a conservative revenue outlook is a series of regulatory changes affecting the distribution of personalized weight management medications. These adjustments are projected to negatively impact first-quarter results by approximately $65 million. The operating environment is growing increasingly complex: the U.S. Food and Drug Administration (FDA) is intensifying its scrutiny of compounded semaglutide products, and pharmaceutical giant Novo Nordisk has filed a patent infringement lawsuit related to a copy of its weight-loss drug.

This regulatory uncertainty directly contributed to the company's disappointing forecast, which triggered a sharp decline in its share price to a new 52-week low of 13.12 euros.

Quarterly Performance Shows Operational Strength

Operationally, the fourth quarter of 2025 presented a solid picture. The company reported a 28% year-over-year increase in revenue, reaching $617.8 million, though this figure slightly missed analyst estimates. Conversely, earnings per share outperformed expectations, coming in at $0.08.

For the full 2026 fiscal year, management now anticipates revenue in the range of $2.7 to $2.9 billion.

Expansion Strategy and Market Reaction

In a strategic move to reduce dependence on the heavily regulated U.S. market, Hims & Hers announced the acquisition of Australian digital health firm Eucalyptus. The transaction, which could be valued at up to $1.15 billion, is intended to accelerate the company's access to international markets.

The market's response to the earnings report and guidance was swift and negative. The company's projection for Q1 2026 revenue—between $600 and $625 million—was significantly below the consensus estimate of approximately $653 million. Prominent financial institutions including Barclays and Morgan Stanley subsequently lowered their price targets on the stock, while BTIG downgraded its rating to "Neutral."

The future trajectory of the stock is likely to hinge on two key factors: how effectively the company navigates its legal dispute with Novo Nordisk, and whether the planned integration of Eucalyptus, expected by mid-2026, can deliver the anticipated growth needed to offset regulatory pressures on its core business.